[1] Christensen PK, Larsen S, Horn T, el al. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy[J]. Kidney Int,2000,58(4):1719-1731. [2] Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System2004 annual data report: atlas of end-stage renal disease in the United States[J]. Am J Kidney Dis,2005,45(1 Suppl 1):A5-A7,S1-S280. [3] 杨松涛, 左力, 杨海燕. 肾小球滤过率计算方程的正确评价[J]. 诊断学理论与实践, 2007,6(6):489-493. [4] 李怡, 李文瑞, 邱文升, 等. 血、尿α1-微球蛋白测定对NIDDM肾病变早期诊断的意义[J]. 中国糖尿病杂志,1996,4(4):202-205. [5] 中华医学会糖尿病分会. 中国2型糖尿病防治指南(2013年版)[J]. 中华糖尿病杂志,2014,22(8):2-42. [6] Molnár M, Wittmann I, Nagy J.Prevalence, course and risk factors of diabetic nephropathy in type-2 diabetes mellitus[J]. Med Sci Monit,2000,6(5):929-936. [7] Andersen S, Jacobsen P, Tarnow L, et al.Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy[J]. Nephrol Dial Transplant,2003, 18(2):293-297. [8] 王强, 杭涛, 邹莺, 等. 不同体质指数人群冠状动脉病变与心外膜脂肪、胰岛素抵抗和C反应蛋白的关系[J]. 中国综合临床,2014,30(4):353-356. [9] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group[J]. BMJ,1998,317(7160):703-713. [10] Hansson L, Zanchetti A, Carruthers SG, et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group[J]. Lancet,1998,351(9118):1755-1762. [11] Chobanian AV, Bakris GL, Black HR, et al.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. JAMA,2003,289(19):2560-2572. [12] Kim HY, Park SY, Lee MH, et al.Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance[J]. J Hepatol,2015,63(2):477-485. |